FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Eric Bjerkholt as chief financial officer (CFO).

加利福尼亚州福斯特城-（商业线）-Mirum Pharmaceuticals，Inc。（纳斯达克股票代码：MIRM）今天宣布任命Eric Bjerkholt为首席财务官（CFO）。

“Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management,” said Chris Peetz, president and chief executive officer at Mirum. “Eric is joining at an important period of growth and global scale for Mirum, and it is a pleasure to have his experience and leadership at Mirum as we continue to execute on numerous initiatives across our rare disease franchises.”.

Mirum总裁兼首席执行官克里斯·佩茨（Chris Peetz）说：“Eric是一家有成就的CFO，在推动财务绩效，业务发展和运营管理方面取得了杰出的业绩。“埃里克正在加入Mirum的一个重要的增长和全球规模的时期，当我们继续在我们罕见的疾病特许经营中执行多项举措时，很高兴在Mirum拥有他的经验和领导力。”。

Mr. Bjerkholt brings extensive business leadership experience from roles served in the biopharmaceutical industry. He comes to Mirum from Chinook Therapeutics, Inc., where he served as CFO overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions.

Bjerkholt先生从生物制药行业的角色中获得了广泛的业务领导经验。他从Chinook Therapeutics，Inc.来到Mirum，在那里他担任CFO，负责监督财务报告，规划和预算，内部控制，投资者关系，设施和信息技术职能。

Prior to Chinook, he served as CFO at Aimmune Therapeutics, Inc. Before Aimmune, Eric worked at Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. Prior to joining industry, Mr. Bjerkholt spent nearly a decade in healthcare investment banking at J.P.

在Chinook之前，他曾在Aimmune Therapeutics，Inc。担任CFO。在Aimmune之前，Eric曾在Sunesis Pharmaceuticals，Inc.，IntraBiotics Pharmaceuticals，Inc.，LifeSpring Nutrition，Inc。和Age Wave，LLC工作。在加入工业之前，Bjerkholt先生在J.P.的医疗投资银行工作了近十年。

Morgan & Company, Inc. He is currently a member of the board of directors of CalciMedica, Inc., Cerus Corporation and Surrozen, Inc. Mr. Bjerkholt holds an MBA from Harvard Business School and a Cand.Oecon degree from the University of Oslo in Norway..

Morgan＆Company，Inc。他目前是CalciMedica，Inc.，Cerus Corporation和Surrozen，Inc。董事会成员.Bjerkholt先生持有哈佛商学院的MBA学位和奥斯陆大学的Cand.Oecon学位。在挪威。。

“Mirum is an exciting company that has achieved significant success in a short period of time,” said Mr. Bjerkholt. I am impressed by the company’s patient focus, scientific rigor, and vibrant culture, all critical elements in building a lasting and successful organization. I believe Mirum is poised for much continued success, and I look forward to helping the company grow and reach as many patients as possible around the world with solutions that address their medical needs.”.

Bjerkholt先生说：“Mirum是一家激动人心的公司，在短时间内取得了重大成功。”。公司以患者为中心，科学严谨，充满活力的文化给我留下深刻印象，这些都是建立持久成功组织的关键要素。我相信Mirum将继续取得成功，我期待通过解决他们医疗需求的解决方案帮助公司在全球范围内成长并接触尽可能多的患者。

In conjunction with his appointment, the Compensation Committee of Mirum’s Board of Directors approved an inducement grant 110,000 shares of common stock, which will have an exercise price per share equal Mirum’s stock closing trading price on September 11, 2023, and 55,000 restricted stock units under Mirum’s 2020 Inducement Plan.

结合他的任命，Mirum董事会补偿委员会批准了110000股普通股的诱导拨款，该股份将于2023年9月11日的行使价等于Mirum的股票结算价，以及55000个限制性股票单位。根据Mirum的2020年诱导计划。

The Compensation Committee approved the awards as an inducement material to Mr. Bjerkholt’s employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to Mr.

根据纳斯达克上市规则5635（c）（4），赔偿委员会批准该奖项作为Bjerkholt先生就业的诱导材料。股票期权将在四年内投资，25%的基础股份在适用的投资开始日期一周年前投资，其余基础股份的余额在36个月后每月投资，具体取决于Mr。

Bjerkholt’s continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to his continued service relationship with Mirum through the applicable vesting dates..

Bjerkholt在适用的调查日期与Mirum的持续服务关系。RSU将投资三年以上，33%的基础股份将在适用的投资开始日期每周年前投资，但须在适用的投资日期内与Mirum继续服务关系。。

About Mirum Pharmaceuticals, Inc.

关于Mirum Pharmaceuticals，股份有限公司。

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.

Mirum Pharmaceuticals，Inc。是一家生物制药公司，致力于改变影响儿童和成人的罕见疾病的治疗方法。Mirum有三种批准的药物：LIVMARLI®（maralixibat）口服液，Cholbam®（胆酸）胶囊和Chenodal®（chenodiol）片剂。

LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older.

LIVMARLI是一种IBAT抑制剂，被批准用于治疗美国（三个月及以上），欧洲（两个月及以上）和加拿大的Alagille综合征患者的胆汁淤积性瘙痒症。Mirum还提交了LIVMARLI在美国批准三个月及以上的PFIC患者的胆汁淤积性瘙痒症，在欧洲批准两个月及以上的PFIC患者。

Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX)..

Cholbam是FDA批准用于治疗由于单一酶缺乏引起的胆汁酸合成障碍，以及对出现体征或症状或肝病的患者辅助治疗过氧化物酶体紊乱。Chenodal已获得FDA的医疗必要性认可，可治疗患有脑腱黄瘤病（CTX）的患者。。

Mirum’s late-stage pipeline includes three investigational treatments for debilitating liver diseases. The LIVMARLI development program includes the Phase 2b EMBARK study for biliary atresia. Mirum’s second investigational IBAT inhibitor is volixibat, which is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis.

Mirum的晚期管道包括三种用于治疗衰弱性肝病的研究性治疗方法。LIVMARLI发展计划包括胆道闭锁的2b期EMBARK研究。Mirum的第二个研究性IBAT抑制剂是volixibat，正在两项潜在的注册研究中进行评估，包括原发性硬化性胆管炎的2b期VISTAS研究和原发性胆汁性胆管炎的2b期VANTAGE研究。

Lastly, Chenodal, is being evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX..

最后，Chenodal正在3期临床研究RESTORE中进行评估，以治疗CTX患者。。

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.

要了解有关Mirum的更多信息，请访问mirumpharma.com，并在Facebook，LinkedIn，Instagram和Twitter上关注Mirum。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements, including those regarding the continued commercial and development success of Mirum products and candidates involve risks and uncertainties.

本新闻稿包含1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条（经修订）含义内的“前瞻性声明”。此类前瞻性声明，包括有关Mirum产品和候选人的持续商业和开发成功涉及风险和不确定性。

The Company’s experience and results may differ materially from the experience and results anticipated in such statements. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions including, but are not limited to, the following factors: the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Mirum’s business and prospects, adverse developments in our focused markets, or adverse developments in the U.S.

本公司的经验和结果可能与本声明中预期的经验和结果有很大不同。这些陈述的准确性受到许多风险，不确定性和假设的影响，包括但不限于以下因素：研发中固有的不确定性；业务和财务规划固有的不确定性，包括但不限于与Mirum业务和前景相关的风险，我们关注市场的不利发展或美国的不利发展。

or global regulatory environment or economies generally; the continued impact of COVID-19 on our business, operations and financial results; and competitive developments. Other factors that might cause such a difference include those discussed in the Company’s filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date.

或全球监管环境或经济普遍；COVID-19对我们的业务，运营和财务成果的持续影响；和竞争发展。可能导致这种差异的其他因素包括公司与美国证券交易委员会的文件中讨论的因素。本新闻稿中包含的所有前瞻性声明仅在其制定之日起发言，并且基于管理层的假设和估计。这样的日期。

Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law..

除法律要求外，Mirum不承担更新此类陈述的义务，以反映发生的事件或发生日期之后存在的情况。。